SEMHF - Siemens Healthineers: The Upside Is Clear To Me Over The Long Term

2024-07-05 10:00:20 ET

Summary

• Siemens Healthineers reported good revenue growth and margin expansion in Q2 2024, with strong performance in Imaging, Varian, and Advanced Therapies segments.
• Despite a recent decline in share price, the company maintains a strong balance sheet and confirms full-year outlook for mid-to-high single-digit growth.
• Analysts have a positive outlook on Healthineers, with price targets ranging from €48 to €75/share and 18 out of 20 analysts recommending a "BUY" or outperform rating.

Dear readers/followers,

In this article, I mean to clarify the overall upside for Siemens Healthineers ( SEMHF ) ( SMMNY ), a company that I not only have invested in, but have significantly put capital into during periods of undervaluation. One of my early articles still has a very impressive 20% overall RoR from back in September of last year. The RoR since my last actual article is one you can find here , and that, unfortunately, is negative for the time being, with the S&P up 8.32% in the while, but Siemens Healthineers down 6.57%.

So, in this article, we'll look at overall company results, and see what upside may be possible here going forward. At the time of my last article, Siemens Healthineers saw good revenue growth, margin improvement, and contract wins, leading to an increase in valuation. I still believed this to be cheap. Since then, the company has declined, and because of the recent quarterly report from 2Q, we'll look at what In this report caused this decline (if anything)....

For further details see: